Your browser doesn't support javascript.
loading
Discovery of a dual pathway aggregation mechanism for a therapeutic constrained peptide.
Chen, Tao; Tang, Shijia; Hecht, Elizabeth S; Yen, Chun-Wan; Andersen, Nisana; Chin, Steven; Cadang, Lance; Roper, Brian; Estevez, Alberto; Rohou, Alexis; Chang, Debby; Dai, Lu; Liu, Peter; Al-Sayah, Mohammad; Nagapudi, Karthik; Lin, Fiona; Famili, Amin; Hu, Chloe; Kuhn, Robert; Stella, Cinzia; Crittenden, Christopher M; Gruenhagen, Jason A; Venkatramani, Cadapakam; Hannoush, Rami N; Leung, Dennis; Vandlen, Richard; Yehl, Peter.
Afiliação
  • Chen T; Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States. Electronic address: chen.tao@gene.com.
  • Tang S; Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Hecht ES; Department of Microchemistry, Proteomics, and Lipidomics, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Yen CW; Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Andersen N; Protein Analytical Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Chin S; Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Cadang L; Protein Analytical Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Roper B; Protein Analytical Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Estevez A; Department of Structural Biology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Rohou A; Department of Structural Biology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Chang D; Department of Drug Delivery, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Dai L; Protein Analytical Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Liu P; Department of Microchemistry, Proteomics, and Lipidomics, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Al-Sayah M; Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Nagapudi K; Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Lin F; Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Famili A; Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Hu C; Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Kuhn R; Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Stella C; Protein Analytical Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Crittenden CM; Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Gruenhagen JA; Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Venkatramani C; Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Hannoush RN; Department of Early Discovery Biochemistry, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Leung D; Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Vandlen R; Department of Protein Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
  • Yehl P; Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
J Pharm Sci ; 110(6): 2362-2371, 2021 06.
Article em En | MEDLINE | ID: mdl-33652014
ABSTRACT
Constrained peptides (CPs) have emerged as attractive candidates for drug discovery and development. To fully unlock the therapeutic potential of CPs, it is crucial to understand their physical stability and minimize the formation of aggregates that could induce immune responses. Although amyloid like aggregates have been researched extensively, few studies have focused on aggregates from other peptide scaffolds (e.g., CPs). In this work, a streamlined approach to effectively profile the nature and formation pathway of CP aggregates was demonstrated. Aggregates of various sizes were detected and shown to be amorphous. Though no major changes were found in peptide structure upon aggregation, these aggregates appeared to have mixed natures, consisting of primarily non-covalent aggregates with a low level of covalent species. This co-existence phenomenon was also supported by two kinetic pathways observed in time- and temperature-dependent aggregation studies. Furthermore, a stability study with 8 additional peptide variants exhibited good correlation between aggregation propensity and peptide hydrophobicity. Therefore, a dual aggregation pathway was proposed, with the non-covalent aggregates driven by hydrophobic interactions, whereas the covalent ones formed through disulfide scrambling. Overall, the workflow presented here provides a powerful strategy for comprehensive characterization of peptide aggregates and understanding their mechanisms of formation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Amiloide Idioma: En Revista: J Pharm Sci Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Amiloide Idioma: En Revista: J Pharm Sci Ano de publicação: 2021 Tipo de documento: Article